Determination of Plasma Heparin Level Improves Identification of Systemic Mast Cell Activation Disease
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Diagnosis of mast cell activation disease (MCAD), i.e. systemic mastocytosis (SM) and idiopathic systemic mast cell activation syndrome (MCAS), usually requires demonstration of increased mast cell (MC) mediator release. Since only a few MC mediators are currently established as biomarkers of MCAD, the sensitivity of plasma heparin level (pHL) as an indicator of increased MC activation was compared with that of serum tryptase, chromogranin A and urinary N-methylhistamine levels in 257 MCAD patients. Basal pHL had a sensitivity of 41% in MCAS patients and 27% in SM patients. Non-pharmacologic stimulation of MC degranulation by obstruction of venous flow for 10 minutes increased the sensitivity of pHL in MCAS patients to 59% and in SM patients to 47%. In MCAS patients tryptase, chromogranin A, and N-methylhistamine levels exhibited low sensitivities (10%, 12%, and 22%, respectively), whereas sensitivities for SM were higher (73%, 63%, and 43%, respectively). Taken together, these data suggest pHL appears more sensitive than the other mediators for detecting systemic MC activity in patients with MCAS. The simple, brief venous occlusion test appears to be a useful indicator of the presence of pathologically irritable MCs, at least in the obstructed compartment of the body.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“However, there are insuf fi cient data to demonstrate their clinical utility in the diagnosis of MCA and MCAS.”
From Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review (2021) · cites this paper as [76]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“approximately 80% of patients clinically demonstrating symptoms consistent with MCA showing increased levels of plasma heparin when measured using a sufficiently sensitive assay [58].”
From Diagnosis of mast cell activation syndrome: a global "consensus-2" (2021) · cites this paper as [58]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Like tryptase, heparin is highly (though not perfectly) specific to the MC [58]”
From Diagnosis of mast cell activation syndrome: a global "consensus-2" (2021) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic criteria and classification of mastocytosis: a consensus proposal
Valent, P., Horny, H.-P., Escribano, L., Longley, B. J., Li, C. Y., Schwartz, L. B., Marone, G., Nuñez, R., Akin, C., Sotlar, K., et al. (2001) · Leukemia Research · doi:10.1016/s0145-2126(01)00038-8 · Cited by 1,108
Valent, P., Akin, C., Escribano, L., Födinger, M., Hartmann, K., Brockow, K., Castells, M., Sperr, W. R., Kluin‐Nelemans, H. C., Hamdy, N. A. T., et al. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01807.x · Cited by 750 · cited 2×
“SM is further divided into several subtypes [6].”
BackgroundMethodValent, P., Akin, C., Arock, M., Brockow, K., Butterfield, J. H., Carter, M. C., Castells, M., Escribano, L., Hartmann, K., Lieberman, P., et al. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000328760 · Cited by 654
Diagnostic Value of Tryptase in Anaphylaxis and Mastocytosis
Schwartz, L. B. (2006) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2006.05.010 · Cited by 477
Differential release of mast cell mediators and the pathogenesis of inflammation
Theoharides, T. C., Kempuraj, D., Tagen, M., Conti, P., & Kalogeromitros, D. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00519.x · Cited by 425
Álvarez-Twose, I., González de Olano, D., Sánchez-Muñoz, L., Matito, A., Esteban-López, M. I., Vega, A., Mateo, M. B., Alonso Díaz de Durana, M. D., de la Hoz, B., del Pozo Gil, M. D., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.02.019 · Cited by 294
Differential release of serotonin and histamine from mast cells
Theoharides, T. C., Bondy, P. K., Tsakalos, N. D., & Askenase, P. W. (1982) · Nature · doi:10.1038/297229a0 · Cited by 244
Epidemiology of systemic mastocytosis in Denmark
Cohen, S. S., Skovbo, S., Vestergaard, H., Kristensen, T., Møller, M., Bindslev‐Jensen, C., Fryzek, J. P., & Broesby‐Olsen, S. (2014) · British Journal of Haematology · doi:10.1111/bjh.12916 · Cited by 234
Sperr, W. R., Jordan, J.-H., Fiegl, M., Escribano, L., Bellas, C., Dirnhofer, S., Semper, H., Simonitsch-Klupp, I., Horny, H.-P., & Valent, P. (2002) · International Archives of Allergy and Immunology · doi:10.1159/000059404 · Cited by 207
A Case of Intestinal Mastocytosis Misdiagnosed as Crohn's Disease
Reggiani, S., Cosso, L., Adriani, A., Pantaleoni, S., Risso, A., Vittone, F., Chiusa, L., Sapone, N., & Astegiano, M. (2015) · Case Reports in Gastroenterology · doi:10.1159/000430946 · Cited by 193
Markers of Mast Cell Degranulation
Hogan, A. D., & Schwartz, L. B. (1997) · Methods · doi:10.1006/meth.1997.0494 · Cited by 178
Isolation and Characterization of Heparin from Human Lung
Metcalfe, D. D., Lewis, R. A., Silbert, J. E., Rosenberg, R. D., Wasserman, S. I., & Austen, K. F. (1979) · Journal of Clinical Investigation · doi:10.1172/jci109613 · Cited by 155
Molderings, G. J., Brettner, S., Homann, J., & Afrin, L. B. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-10 · Cited by 149 · cited 4×
“Data from 257 Caucasian patients (for details, see Table 2) presenting consecutively between May 2005 and December 2013 with MCAD diagnosed per current criteria [1,3,4,6] were included in this study.”
BackgroundMethodInfluentialSelf-citationRönnberg, E., Melo, F. R., & Pejler, G. (2012) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155412458927 · Cited by 138
Mast cell activation syndrome: A newly recognized disorder with systemic clinical manifestations
Hamilton, M. J., Hornick, J. L., Akin, C., Castells, M. C., & Greenberger, N. J. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.04.037 · Cited by 132 · cited 3×
“Data from 257 Caucasian patients (for details, see Table 2) presenting consecutively between May 2005 and December 2013 with MCAD diagnosed per current criteria [1,3,4,6] were included in this study.”
BackgroundMethodPrevalence of indolent systemic mastocytosis in a Dutch region
van Doormaal, J. J., Arends, S., Brunekreeft, K. L., van der Wal, V. B., Sietsma, J., Vader, P. C. V. V., Elberink, J. N. G. O., Kluin‐Nelemans, H. C., van der Veer, E., & de Monchy, J. G. R. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.10.015 · Cited by 114
Bochenek, G. (2004) · Thorax · doi:10.1136/thx.2003.013573 · Cited by 106
Familial Occurrence of Systemic Mast Cell Activation Disease
Molderings, G. J., Haenisch, B., Bogdanow, M., Fimmers, R., & Nöthen, M. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076241 · Cited by 94 · cited 1×
“For diagnostic purposes, presence of MC mediator-related symptoms was assessed by a validated questionnaire [10,13].”
MethodSelf-citationEosinophils as a novel cell source of prostaglandin D2: autocrine role in allergic inflammation
Luna-Gomes, T., Magalhães, K. G., Mesquita-Santos, F. P., Bakker-Abreu, I., Samico, R. F., Molinaro, R., Calheiros, A. S., Diaz, B. L., Bozza, P. T., Weller, P. F., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101806 · Cited by 87
Butterfield, J. H., & Weiler, C. R. (2008) · International Archives of Allergy and Immunology · doi:10.1159/000144042 · Cited by 81
Monitoring mast cell activation by prostaglandin D2 in vivo
Dahlen, S.-E. (2004) · Thorax · doi:10.1136/thx.2004.026641 · Cited by 77
Prasad, P., Yanagihara, A. A., Small-Howard, A. L., Turner, H., & Stokes, A. J. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.5024 · Cited by 72
Serum tryptase levels and markers of renal dysfunction in a population with chronic kidney disease
Sirvent, A. E., González, C., Enríquez, R., Fernández, J., Millán, I., Barber, X., & Amorós, F. (2010) · Journal of Nephrology · doi:10.1093/joneph/23.3.282 · Cited by 66
Ravi, A., Butterfield, J., & Weiler, C. R. (2014) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2014.06.011 · Cited by 63 · cited 3×
“Elevated levels were detected in 68% of 25 patients investigated [35].”
Backgroundvan Doormaal, J. J., van der Veer, E., van Voorst Vader, P. C., Kluin, P. M., Mulder, A. B., van der Heide, S., Arends, S., Kluin‐Nelemans, J. C., Oude Elberink, J. N. G., & de Monchy, J. G. R. (2012) · Allergy · doi:10.1111/j.1398-9995.2012.02809.x · Cited by 63
Morrow, J. D., Guzzo, C. A., Lazarus, G. S., Oates, J. A., & Roberts, L. J. (1995) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12606209 · Cited by 56
Survey of aspirin administration in systemic mastocytosis
Butterfield, J. H. (2009) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2009.01.001 · Cited by 54
Mechanical loading promotes mast cell degranulation via RGD-integrin dependent pathways
Fowlkes, V., Wilson, C. G. M., Carver, W. E., & Goldsmith, E. C. (2012) · Journal of Biomechanics · doi:10.1016/j.jbiomech.2012.11.014 · Cited by 51
On the role of PGD2 metabolites as markers of mast cell activation in asthma.
O’Sullivan, S. (1999) · PubMed · Cited by 50
The genetic basis of mast cell activation disease - looking through a glass darkly
Molderings, G. J. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.09.001 · Cited by 50
Self-citationSurrogate Markers of Disease in Mastocytosis
Akin, C., & Metcalfe, D. D. (2002) · International Archives of Allergy and Immunology · doi:10.1159/000048184 · Cited by 49
Haenisch, B., Nöthen, M. M., & Molderings, G. J. (2012) · Immunology · doi:10.1111/j.1365-2567.2012.03627.x · Cited by 48
Self-citationIncreased leukotriene E4 excretion in systemic mastocytosis
Butterfield, J. H. (2010) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2010.03.003 · Cited by 42 · cited 1×
“Tryptase level in blood > 20 ng/ml SM: ~ 80–85% ([16]; further references therein); 77% [39] in the absence of hematologic malignancies and end-stage kidney disease specific for mast cells; 10% falsely elevated results due to interference with rheumatoid factor [45] MCAS: 8% [40]; 22% [41]; 0% [42, 43]; 21% [39]; 33%…”
BackgroundDi Lorenzo, G., Pacor, M. L., Vignola, A. M., Profita, M., Esposito‐Pellitteri, M., Biasi, D., Corrocher, R., & Caruso, C. (2002) · Allergy · doi:10.1034/j.1398-9995.2002.23767.x · Cited by 40
Clinical correlates of blood serotonin levels in patients with mastocytosis
Kushnir‐Sukhov, N. M., Brittain, E., Scott, L., & Metcalfe, D. D. (2008) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2008.02047.x · Cited by 40 · cited 1×
“Tryptase level in blood > 20 ng/ml SM: ~ 80–85% ([16]; further references therein); 77% [39] in the absence of hematologic malignancies and end-stage kidney disease specific for mast cells; 10% falsely elevated results due to interference with rheumatoid factor [45] MCAS: 8% [40]; 22% [41]; 0% [42, 43]; 21% [39]; 33%…”
BackgroundAkhavein M, A., Patel, N. R., Muniyappa, P. K., & Glover, S. C. (2012) · Gastroenterology Research and Practice · doi:10.1155/2012/950582 · Cited by 38
Evidence for Mast Cell Activation in Patients with Therapy-Resistant Irritable Bowel Syndrome
Frieling, T., Meis, K., Kolck, U., Homann, J., Hülsdonk, A., Haars, U., Hertfelder, H.-J., Oldenburg, J., Seidel, H., & Molderings, G. (2011) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0029-1245707 · Cited by 38
Self-citationCraig, S. S., Irani, A. M., Metcalfe, D. D., & Schwartz, L. B. (1993) · PubMed · Cited by 38
A concise, practical guide to diagnostic assessment for mast cell activation disease
Afrin, L. B., & Molderings, G. J. (2014) · World Journal of Hematology · doi:10.5315/wjh.v3.i1 · Cited by 37
Self-citationNew aspects of liver abnormalities as part of the systemic mast cell activation syndrome
Alfter, K., Von Kügelgen, I., Haenisch, B., Frieling, T., Hülsdonk, A., Haars, U., Rolfs, A., Noe, G., Kolck, U. W., Homann, J., et al. (2009) · Liver International · doi:10.1111/j.1478-3231.2008.01839.x · Cited by 35
Self-citationBleeding diathesis in patients with mast cell activation disease
Seidel, H., Oldenburg, J., Meis, K., Kolck, U., Homann, J., Hertfelder, H.-J., & Molderings, G. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-05-0351 · Cited by 34
Self-citationYang, W., Chen, J.-Y., & Zhou, L. (2009) · Journal of Environmental Pathology Toxicology and Oncology · doi:10.1615/jenvironpatholtoxicoloncol.v28.i3.30 · Cited by 33
A concise, practical guide to diagnostic assessment for mast cell activation disease
Afrin, L. B., & Molderings, G. J. (2014) · World Journal of Hepatology · doi:10.5315/wjh.v3.i1.1 · Cited by 33
Self-citationPardanani, A. D., Chen, D., Abdelrahman, R. A., Reichard, K. K., Zblewski, D., Wood, A. J., McClure, R. F., Butterfield, J. H., Hanson, C. A., & Tefferi, A. (2013) · Leukemia · doi:10.1038/leu.2013.227 · Cited by 32
Sargur, R., Cowley, D., Murng, S., Wild, G., Green, K., Shrimpton, A., & Egner, W. (2011) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2010.04287.x · Cited by 27
Comparison of serum tryptase and urine N-methylhistamine in patients with suspected mastocytosis
van Toorenenbergen, A. W., & Oranje, A. P. (2005) · Clinica Chimica Acta · doi:10.1016/j.cccn.2005.03.041 · Cited by 27
The measurement of leukotrienes in urine as diagnostic option in systemic mastocytosis.
Raithel, M., Zopf, Y., Kimpel, S., Naegel, A., Molderings, G. J., Buchwald, F., Schultis, H.-W., Kressel, J., Hahn, E. G., & Konturek, P. C. (2011) · PubMed · Cited by 23
Self-citationPolycythemia From Mast Cell Activation Syndrome: Lessons Learned
Afrin, L. B., & Hamm, L. L. (2011) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31821d41dd · Cited by 21
Vorkommen und Bedeutung des körpereigenen Heparins
Studer, A. (1954) · Cellular and Molecular Life Sciences · doi:10.1007/bf02158526 · Cited by 15
Jaques, L. B. (2008) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0028-1087139 · Cited by 10
Quintás-Cardama, A., Sever, M., Cortes, J., Kantarjian, H., & Verstovsek, S. (2013) · Leukemia & Lymphoma · doi:10.3109/10428194.2012.763121 · Cited by 8
Endogenous heparin—a protective marker in patients with myocardial infarction
Władysław, S. (2002) · Coronary Artery Disease · doi:10.1097/00019501-200212000-00007 · Cited by 8
Physiological, Pathophysiological and Therapeutic Impact of the Enteric Serotonergic System
Molderings, G. J. (2012) · Arzneimittelforschung · doi:10.1055/s-0032-1306321 · Cited by 7
Self-citationSchäfer, D., Dreßen, P., Brettner, S., Rath, N.-F., Molderings, G. J., Jensen, K., & Ziemann, C. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0213-2 · Cited by 7
Self-citationKassab, D., Koterba, A. P., Jiang, Y., & Akin, C. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.12.268 · Cited by 6
Clergue, O., Jones, N. B., Sévenet, N., Quénel-Tueux, N., & Debled, M. (2015) · Bulletin du Cancer · doi:10.1016/j.bulcan.2015.01.010 · Cited by 3
Butterfield, J. H., & Weiler, C. R. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.12.528 · Cited by 2
Ravi, A., Butterfield, J. H., & Weiler, C. R. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.12.1088 · Cited by 1
Research works printed but not linked: 2
- A Studer, 1954, Occurrence and significance of endogenous heparin, Experientia, 10, 148
- S Stefanov, 2013, Immunocytochemical expression of Chromogranin A in mast cells in the canine paranasal sinus, Revue Méd Vét, 164, 453
Cited by
Mast cell activation syndromes
Akin, C. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.06.007 · Cited by 177
Theoharides, T. C., Tsilioni, I., & Ren, H. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1596800 · Cited by 120
Valent, P., Bonadonna, P., Hartmann, K., Broesby-Olsen, S., Brockow, K., Butterfield, J. H., Triggiani, M., Lyons, J. J., Oude Elberink, J. N. G., Arock, M., et al. (2019) · International Archives of Allergy and Immunology · doi:10.1159/000501079 · Cited by 146
Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management
Castells, M., & Butterfield, J. (2019) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2019.02.002 · Cited by 135
Weiler, C. R., Austen, K. F., Akin, C., Barkoff, M. S., Bernstein, J. A., Bonadonna, P., Butterfield, J. H., Carter, M., Fox, C. C., Maitland, A., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.08.023 · Cited by 123
Metadata
- Authors
- Vysniauskaite, M., Hertfelder, H.-J., Oldenburg, J., Dreßen, P., Brettner, S., Homann, J., & Molderings, G. J.
- Affiliations
- University Hospital Bonn (DE)
- St. Franziskus Hospital (DE)
- Corresponding author
- Molderings, Gerhard J.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-04-24
- Volume
- 10
- Issue
- 4
- Pages
- e0124912
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4409380
- OpenAlex
- W2093536852
- Cited by
- 30
- References
- 58
- Citations by year
- 2024: 3 · 2022: 1 · 2021: 2 · 2020: 2 · 2019: 7 · 2018: 4 · 2017: 8 · 2016: 2 · 2015: 1
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Rheumatology › Eosinophilic Disorders and Syndromes
- Keywords
- systemic mastocytosis, mast cell degranulation, venous occlusion test, tryptase, chromogranin A, N-methylhistamine, mast cell mediators, diagnostic sensitivity, biomarkers
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Anticoagulants, Female, Heparin, Humans, Male, Mast Cells, Mastocytosis, Methylhistamines, Middle Aged, Sensitivity and Specificity, Reproducibility of Results, Biomarkers, Chromogranin A, Tryptases, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.